

Pharmaceutical Prices and India

Sudip Chaudhuri
Professor of Economics
Indian Institute of Management Calcutta

Seminar on Pharmaceutical Pricing and
Regulatory Framework for Affordable Prices
NPPA in collaboration with DFID
New Delhi, April 12, 2008

What has happened in India

- Remarkable growth of the Industry
- World wide recognition as a low cost producer of quality drugs:
 - ARV prices and accessibility
- But drugs which can be produced do not reach the people who need them
 - India has one of the worst record in terms of access to essential medicines


What is happening in India

- Product patents introduced in 2005
- Exciting news: Mailbox and restricting product patent claims (Section 3(d)):
 - Novartis' Gleevec (imatinib mesylate)
 - Gliead's Viread (tenofovir disoproxil fumarate)
 - Etc
- Dynamism of Indian generic companies has not waned after TRIPS– in fact, a section of the industry is now even more dynamic
- New Pharmaceutical policy yet to be announced


We focus here on

The Impact of the Dynamism of
the Indian Generic Companies on
Access to Medicines

Responses of Indian generic companies to TRIPS: Major opportunities identified




Destination of Pharmaceutical Exports from india, 2005-06



- Europe
- America
- Asia (excl. Middle East)
- Africa
- Middle East
- Others

Exports markets in USA

Responses of Indian generic companies



So

- Affordability improving in rich countries
- But in poor countries prospects bleak unless concerted action taken up both internationally and nationally:
 - Patented drugs: In the longer term context what would be crucial is proper compulsory licensing system in countries. In India:
 - procedure specified is cumbersome
 - entire process is excessively legalistic and provides the patentees the opportunity to manipulate by litigation
- Priority to public health and subsidized insurance
- Just Drug Price Control will not be enough

Thank you

sudip@iimcal.ac.in